

Mundipharma brings its cancer supportive care expertise to Vietnam after signing agreement with Helsinn Group for ALOXI® (palonosetron HCl)

- *Mundipharma and Helsinn Group expand exclusive licensing and distribution agreement for anti-emetic medicine ALOXI®*
- *This agreement builds on similar existing arrangements in a range of territories.*

SINGAPORE and LUGANO, August 15, 2018: Mundipharma and Helsinn Group signed a licensing and distribution agreement for the anti-emetic agent ALOXI® in Vietnam, extending an international collaboration.

ALOXI® (palonosetron **hydrochloride**), a 5-HT₃ receptor antagonist was approved in Vietnam. For additional information please see the [Product Information](#).

Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the most common and distressing side effects of cancer chemotherapy. Mundipharma and Helsinn are experts in the CINV field with decades of shared experience and are currently providing medicine to CINV sufferers.

Mundipharma CEO, Raman Singh said, “This important extension of our portfolio in Vietnam offers relief to patients suffering from the side effects of chemotherapy and enables patients and healthcare providers to benefit from our expertise in this area.”

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “Helsinn and Mundipharma have an effective, longstanding partnership and Mundipharma successfully markets, promotes and distributes a number of our products across a range of territories. We’re delighted to be able to extend this relationship through this agreement.”

ENDS

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco, and China, as well as a product presence in approximately 190 countries globally.

For more information, please visit www.helsinn.com

About Mundipharma

Mundipharma is a network of independent associated companies, which are privately owned entities, covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life.

Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

For further information, please contact:

Helsinn Group Media Contact

Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Info-hhc@helsinn.com

*For more information, please visit www.helsinn.com and follow us on [Twitter](#), [LinkedIn](#)
and [Vimeo](#)*

Mundipharma:

Stephenie Vasko

Head of Communications & Digital Strategy – Asia Pacific, Middle East, Africa & Latin America

+65-6303-9732 | stephenie.vasko@mundipharma.com.sg